Pharvaris secured $80 million Series C co-led by Viking Global Investors and General Atlantic co-led the financing, with participation by Cormorant Asset Management.
Pharvaris, a Zug, Switzerland-based clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients, announced securing a $80 million Series C financing round.
The money was raised from investors co-led by Viking Global Investors and General Atlantic with participation by Cormorant Asset Management. Current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners, and Venrock Healthcare Capital Partners also participated in the round.
Pharvaris, founded by CEO Berndt Modig, is focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications,
Pharvaris previously raised about $80 million.